Ginkgo Bioworks Holdings, Inc. (DNA)
| Market Cap | 592.93M |
| Revenue (ttm) | 237.42M |
| Net Income (ttm) | -472.08M |
| Shares Out | 58.53M |
| EPS (ttm) | -8.92 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,552,020 |
| Open | 9.97 |
| Previous Close | 9.76 |
| Day's Range | 9.78 - 10.44 |
| 52-Week Range | 5.00 - 16.85 |
| Beta | 1.49 |
| Analysts | Hold |
| Price Target | 8.50 (-16.09%) |
| Earnings Date | Aug 7, 2025 |
About DNA
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell programming in the United States. It operates through Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics and antibody developability Datapoints services, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms... [Read more]
Financial Performance
In 2024, Ginkgo Bioworks Holdings's revenue was $227.04 million, a decrease of -9.71% compared to the previous year's $251.46 million. Losses were -$547.03 million, -38.73% less than in 2023.
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for DNA stock is "Hold." The 12-month stock price target is $8.5, which is a decrease of -16.09% from the latest price.
News
Ginkgo Bioworks Launches ADME Profiling Service Using Lab Automation, Offering a US-based Operation That Will Match or Beat Pricing Quotes from Chinese or Other International Vendors
Ginkgo Bioworks launches cost-effective, high-throughput ADME profiling service to accelerate small molecule drug discovery with model-ready datasets BOSTON , July 17, 2025 /PRNewswire/ -- Ginkgo Biow...
Ginkgo Bioworks Announces Appointment of Steven Coen as Chief Financial Officer
BOSTON , May 21, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA, "Ginkgo" or the "Company"), which is building the leading platform for cell programming and biosecurity, today announced that Mark Dmy...
Twist Bioscience and Ginkgo Bioworks Revise Collaboration
SOUTH SAN FRANCISCO, Calif. & BOSTON--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a core mid-cap growth and value equity company in the life sciences segment of the health care secto...
Ginkgo Bioworks Holdings, Inc. (DNA) Q1 2025 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q1 2025 Results Conference Call May 6, 2025 5:00 PM ET Company Participants Daniel Marshall - Sr. Manager, Communications and Ownership Jason Kelly - Co-Foun...
Ginkgo Bioworks Reports First Quarter 2025 Financial Results
Ginkgo provides an update on its restructuring, including progress towards its expanded $250 million cost savings target Ginkgo and partners awarded $29 million contract by ARPA-H to develop distribut...
Phytolon and Ginkgo Bioworks Boost Natural Food Colors by Hitting Full-Project Milestone, Nearly Tripling the Manufacturing Efficiency of Phytolon's Innovative Colors
Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficienc...
Ginkgo Bioworks Announces Date of First Quarter 2025 Results Presentation
Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON , April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leadi...
Ginko Automation Partners with Aura Genetics to Accelerate Direct-to-Consumer Testing and Innovation
BOSTON , April 22, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Ginkgo Automation will design and...
Ginkgo Bioworks Teams Up with Partners on ARPA-H Project to Stabilize Pharmaceutical Supply Chains - Using Amber Waves of Grain
Ginkgo Bioworks and partners awarded $29 million contract by ARPA-H to develop distributed manufacturing of essential medicines using wheat germ cell-free expression systems BOSTON , April 10, 2025 /P...
Plex Research Partners With Ginkgo Bioworks on Artificial Intelligence (AI)-Powered Drug Discovery to Identify Novel Disease Mechanisms and Pathways
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Plex Research is partnering with Ginkgo Bioworks to use AI to deepen understanding of the mechanisms of action of existing drugs.
Ginkgo Bioworks: Revenue Struggles Continue
Ginkgo Bioworks missed Q4 revenue estimates and issued extremely weak 2025 revenue guidance. Despite improving losses and cash burn, financial flexibility is decreasing, with cash reserves dropping si...
2025 Is Make Or Break For Ginkgo Bioworks
Ginkgo Bioworks' restructuring has resulted in a dramatic reduction in cash burn in recent quarters. Ginkgo remains a long way from breakeven though and growth is expected to be poor in 2025. Unless G...
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were higher this morning, with the Dow futures gaining around 100 points on Wednesday.
Ginkgo Bioworks Holdings, Inc. (DNA) Q4 2024 Earnings Call Transcript
Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) Q4 2024 Earnings Conference Call February 25, 2025 5:30 PM ET Company Participants Joseph Fridman - Director, Communications and Corporate Affairs Jason Kell...
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results
Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an expanded cost savings target Cell Engi...
Ginkgo Bioworks integrates Callisto for difficult-to-automate NGS processes in their high-throughput lab
BOSTON , Feb. 21, 2025 /PRNewswire/ -- Volta Labs , a leading genomics applications company, and Ginkgo Bioworks, (NYSE: DNA), which is building a leading platform for cell programming and biosecurit...
Ginkgo Bioworks Partners with HaDEA in Up to €24 Million Consortium Project to Deliver Next-Generation 'Agnostic Diagnostics' for Respiratory Viruses at the Point of Care
International consortium to develop rapid metagenomic NGS solutions that can identify known and novel respiratory pathogens, reduce time-to-diagnosis, and enhance hospital decision-making and public h...
Ginkgo Bioworks Announces Date of Fourth Quarter and Full Year 2024 Results Presentation
Presentation and Q&A session scheduled for post-market on Tuesday, February 25, 2025 BOSTON , Feb. 18, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) ("Ginkgo"), which is building the...
Ginkgo Bioworks to Host 6th Annual Ferment as Boston-based Conference Series
Evolution of Ferment conference to kick off Summer 2025 BOSTON , Feb. 6, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, ...
Ginkgo Automation to Deploy Flexible Laboratory Automation System for Cutting-Edge Biofuels and Bioproducts Research at Great Lakes Bioenergy Research Center (GLBRC)
Customizable, anaerobic-enabled system aims to accelerate discovery and development of sustainable biofuels at the University of Wisconsin–Madison's GLBRC BOSTON , Jan. 23, 2025 /PRNewswire/ -- Ginkgo...
SaponiQx, Probius, and Ginkgo Bioworks Unite to Revolutionize Vaccine Adjuvant Development
LEXINGTON, Mass. & FREMONT, Calif.--(BUSINESS WIRE)--SaponiQx, a leader in saponin-based adjuvant discovery, is pleased to announce a strategic collaboration with Probius, a pioneer in quantum molecul...
Ginkgo Bioworks Partners with Universal Cells, an Astellas Company, to Advance Next-Generation iPSC-Derived Cell Therapies for Solid Tumors
Collaboration leverages Ginkgo's cell engineering and screening platform to enhance the potency and persistence of Universal Cells' iPSC-derived immune cell therapeutics BOSTON , Jan. 13, 2025 /PRNews...
Rapid Rise of Synthetic Biology Fuels Enzymatic DNA Synthesis Boom Across Biopharma and Genomics
Dublin, Jan. 09, 2025 (GLOBE NEWSWIRE) -- The "Enzymatic DNA Synthesis Market by Service, by Application, by End-User, and By Region" report has been added to ResearchAndMarkets.com's offering. The gl...
Ginkgo Bioworks Announces Participation in the 43rd Annual J.P. Morgan Healthcare Conference
BOSTON , Jan. 9, 2025 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced that Co-Founder and CEO, Jason Kelly, is...
Ginkgo Bioworks Awarded $9.4 Million in Partnership with Carnegie Mellon University to Develop Implantable Cell-Based Bioelectronic Devices for Disease Treatment Under ARPA-H's REACT Program
Ginkgo Bioworks to apply its mammalian cell engineering expertise to develop new cell-based systems for treating and monitoring endocrine disorders BOSTON , Dec. 17, 2024 /PRNewswire/ -- Ginkgo Biowor...